News

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the ...
Biogen’s salanersen shows promise in SMA, heads toward registrational trials
Based on these encouraging Phase 1 data, Biogen (NASDAQ:BIIB) is engaging with regulators to advance its investigational ...
The Pharma Letter15h
Salanersen shines in early spinal muscular atrophy research
Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim ...
TMCnet1d
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
The cumulative data from the Phase 1 study indicate that salanersen has a generally well tolerated safety profile at both the 40 mg and 80 mg doses, with most adverse events (AEs) mild to moderate in ...